Skip to main content
. 2017 Aug 17;24(11):1461–1468. doi: 10.1177/1352458517726380

Figure 1.

Figure 1.

The impact of cladribine on EQ-5D.

People with relapsing MS were treated with either placebo (circle; n = 281–310) or 3.5-mg/kg cladribine (diamond; n = 306–319) on weeks 0, 5, 48 and 52 or treated with 5.25 mg/kg (hexagon; n = 320–329) by receiving additional oral doses in weeks 9 and 13. The results represent the mean ± standard error of the mean. *p < .05, **p < .01 compared to placebo. Inverse triangles indicate time points of drug administration.